This study, conducted by Frank A. Scappaticci and colleagues, aimed to evaluate the risk of arterial thromboembolic events in patients with metastatic carcinomas treated with bevacizumab and chemotherapy compared to those treated with chemotherapy alone. The analysis was based on data from five randomized controlled trials involving 1745 patients with metastatic colorectal, breast, or non-small-cell lung cancer. The results showed that combination therapy with bevacizumab and chemotherapy increased the risk of arterial thromboembolic events (HR = 2.0, 95% CI = 1.05 to 3.75; P = .031) but not venous thromboembolic events (HR = 0.89, 95% CI = 0.66 to 1.20; P = .44). The absolute rate of arterial thromboembolic events was 5.5 per 100 person-years for the combination therapy group and 3.1 per 100 person-years for the chemotherapy alone group. Factors associated with an increased risk of arterial thromboembolic events included a history of arterial thromboembolic event and age 65 years or older. Baseline or on-study aspirin use was associated with modest increases in grade 3 and 4 bleeding events. The study concluded that combination therapy with bevacizumab and chemotherapy increased the risk of arterial thromboembolic events but not venous thromboembolic events, and that these risk factors should be considered when making treatment decisions for individual patients.This study, conducted by Frank A. Scappaticci and colleagues, aimed to evaluate the risk of arterial thromboembolic events in patients with metastatic carcinomas treated with bevacizumab and chemotherapy compared to those treated with chemotherapy alone. The analysis was based on data from five randomized controlled trials involving 1745 patients with metastatic colorectal, breast, or non-small-cell lung cancer. The results showed that combination therapy with bevacizumab and chemotherapy increased the risk of arterial thromboembolic events (HR = 2.0, 95% CI = 1.05 to 3.75; P = .031) but not venous thromboembolic events (HR = 0.89, 95% CI = 0.66 to 1.20; P = .44). The absolute rate of arterial thromboembolic events was 5.5 per 100 person-years for the combination therapy group and 3.1 per 100 person-years for the chemotherapy alone group. Factors associated with an increased risk of arterial thromboembolic events included a history of arterial thromboembolic event and age 65 years or older. Baseline or on-study aspirin use was associated with modest increases in grade 3 and 4 bleeding events. The study concluded that combination therapy with bevacizumab and chemotherapy increased the risk of arterial thromboembolic events but not venous thromboembolic events, and that these risk factors should be considered when making treatment decisions for individual patients.